» Authors » Michal S Barski

Michal S Barski

Explore the profile of Michal S Barski including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 39
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneiderman B, Barski M, Maertens G
Front Med (Lausanne) . 2022 May; 9:889621. PMID: 35547224
Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus most prevalent in southwestern Japan, sub-Saharan Africa, Australia, South America, and the Caribbean. Latest figures approximate 10 million people worldwide...
2.
Barski M, Vanzo T, Zhao X, Smith S, Ballandras-Colas A, Cronin N, et al.
Nat Commun . 2021 Oct; 12(1):5927. PMID: 34611170
No abstract available.
3.
Barski M, Vanzo T, Zhao X, Smith S, Ballandras-Colas A, Cronin N, et al.
Nat Commun . 2021 Aug; 12(1):4996. PMID: 34404793
Between 10 and 20 million people worldwide are infected with the human T-cell lymphotropic virus type 1 (HTLV-1). Despite causing life-threatening pathologies there is no therapeutic regimen for this deltaretrovirus....
4.
Barski M, Minnell J, Hodakova Z, Pye V, Nans A, Cherepanov P, et al.
Nat Commun . 2020 Oct; 11(1):5043. PMID: 33028863
Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus and the most oncogenic pathogen. Many of the ~20 million HTLV-1 infected people will develop severe leukaemia or an ALS-like...
5.
Barski M, Minnell J, Maertens G
Front Microbiol . 2019 Sep; 10:1877. PMID: 31474960
More than 10 million people worldwide are infected with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to severe adult T-cell leukemia/lymphoma (ATLL)...